Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases -WAYNE, Pa., Feb. 12, 2025 ...

Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...

DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report ... combination of PB and TURSO and their complementary mechanisms of action will allow to synergistically target abnormal cell ...

On the other hand, mechanisms of acquired resistance to 'pathway-targeted' drugs, such as the various clinically active kinase inhibitors, have been somewhat more straightforward to elucidate and ...

Glycogen synthase kinase 3 (GSK3 ... Figure 4: The molecular mechanism by which phosphorylation inhibits GSK3. Figure 5: Several signalling pathways induce the inhibition of GSK3 by ...

Endometriosis, a prevalent gynecological condition, is characterized by the growth of endometrial-like tissues outside the ...

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered biologics.

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.